Psoriasiform eruption triggered by a dipeptidyl peptidase IV inhibitor.

Authors :: Mas-Vidal A
Santos-Juanes J
Esteve-Martinez A
Caminal-Montero L
Coto-Segura P
Source :: The Australasian journal of dermatology [Australas J Dermatol] 2012 Feb; Vol. 53 (1), pp. 70-2. Date of Electronic Publication: 2011 Jun 13.
Publication Year :: 2012
Abstract: Psoriatic patients have a higher prevalence of diabetes mellitus type 2 (DM). Since dipeptidyl peptidase IV (DPP-IV) dysregulation is present in DM and psoriasis, DPP-IV inhibitors have been proposed as therapeutic agents for both conditions. We report a psoriasiform eruption induced by sitagliptin, a DPP-IV inhibitor. The role of DPP-IV in the pathogenesis of DM is well established; however data on psoriatic patients is contradictory. More studies are required to elucidate the effect of DPP-IV inhibitors and their relationship with DM and psoriasis.<br /> (© 2011 The Authors. Australasian Journal of Dermatology © 2011 The Australasian College of Dermatologists.)